Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from the blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics.
The Acute Renal Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Renal Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure and features dormant and discontinued projects.
Key Targets in the Acute Renal Failure Pipeline Products Market
The key targets in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase, Alkaline Phosphatase, Free Radical, Peroxisome Proliferator Activated Receptor Delta, Renalase, Alpha 1 Adrenergic Receptor, Alpha 2B Adrenergic Receptor, Atrial Natriuretic Peptide Receptor 1, C-X-C Chemokine Receptor Type 4, and others.
Acute Renal Failure Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Acute Renal Failure Pipeline Products Market
The key mechanisms of action in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor Agonist, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase Inhibitor, Alkaline Phosphatase Replacement, Free Radical Scavenger, Peroxisome Proliferator Activated Receptor Delta Agonist, Renalase Activator, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2B Adrenergic Receptor Agonist, Atrial Natriuretic Peptide Receptor 1 Agonist, C-X-C Chemokine Receptor Type 4 Agonist, and others.
Acute Renal Failure Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Acute Renal Failure Pipeline Products Market
The key routes of administration in the Acute Renal Failure pipeline products market are intravenous, oral, subcutaneous, intramuscular, intrathecal, intravenous bolus, parenteral, topical, inhalational, intraarticular, and others.
Acute Renal Failure Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Acute Renal Failure Pipeline Products Market
The key molecule types in the Acute Renal Failure pipeline products market are small molecule, recombinant protein, cell therapy, recombinant enzyme, synthetic peptide, fusion protein, antisense RNAi oligonucleotide, biologic, recombinant peptide, monoclonal antibody, and others.
Acute Renal Failure Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Acute Renal Failure Pipeline Products Market
Some of the major companies in the Acute Renal Failure pipeline products market are Angion Biomedica Corp, Arch Biopartners Inc, Goldilocks Therapeutics Inc, Johnson & Johnson, Mitobridge Inc, Q BioMed Inc, TES Pharma SRL, Alloksys Life Sciences BV, Am-Pharma BV, and Amniotics AB.
Acute Renal Failure Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Angiopoietin 1 Receptor, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase, Alkaline Phosphatase, Free Radical, Peroxisome Proliferator Activated Receptor Delta, Renalase, Alpha 1 Adrenergic Receptor, Alpha 2B Adrenergic Receptor, Atrial Natriuretic Peptide Receptor 1, C-X-C Chemokine Receptor Type 4, and Others |
Key mechanism of action | Angiopoietin 1 Receptor Agonist, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase Inhibitor, Alkaline Phosphatase Replacement, Free Radical Scavenger, Peroxisome Proliferator Activated Receptor Delta Agonist, Renalase Activator, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2B Adrenergic Receptor Agonist, Atrial Natriuretic Peptide Receptor 1 Agonist, C-X-C Chemokine Receptor Type 4 Agonist, and Others |
Key routes of administration | Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal, Intravenous Bolus, Parenteral, Topical, Inhalational, Intraarticular, and Others |
Key molecule type | Small Molecule, Recombinant Protein, Cell Therapy, Recombinant Enzyme, Synthetic Peptide, Fusion Protein, Antisense RNAi Oligonucleotide, Biologic, Recombinant Peptide, Monoclonal Antibody, and Others |
Major companies | Angion Biomedica Corp, Arch Biopartners Inc, Goldilocks Therapeutics Inc, Johnson & Johnson, Mitobridge Inc, Q BioMed Inc, TES Pharma SRL, Alloksys Life Sciences BV, Am-Pharma BV, and Amniotics AB |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from the company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Am-Pharma BV
Amniotics AB
Anagenics Ltd
Angion Biomedica Corp
Angiotensin Therapeutics Inc
Arch Biopartners Inc
Ashvattha Therapeutics LLC
Axolo Pharma Inc
Balmes Transplantation SAS
Bessor Pharma LLC
CFM Pharma Holding BV
Chaperone Pharma BV
Claritas Pharmaceuticals Inc
Curigin Co Ltd
Cypralis Ltd
DURECT Corp
Evotec SE
Exponential Biotherapies Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
GeneScience Pharmaceuticals Co Ltd
Goldilocks Therapeutics Inc
Guard Therapeutics International AB
Haisco Pharmaceutical Group Co Ltd
HemaFlo Therapeutics Inc
Hybridize Pharma BV
iCELL Biotechnology Co Ltd
ILIAS Biologics Inc
Johnson & Johnson
Kantum Pharma Inc
Klotho Therapeutics Inc
Kringle Pharma Inc
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Meridigen Biotech Co Ltd
Metro International Biotech LLC
Mission Therapeutics Ltd
Mitobridge Inc
Mitotech SA
Mitotherapeutix LLC
NeoProgen Inc
Nephraegis Therapeutics
Orgenesis Inc
Paranta Biosciences Ltd
Pharmazz Inc
Pharmicell Co Ltd
Pharming Group NV
Praetego Inc
Q BioMed Inc
Radikal Therapeutics Inc
Rediscovery Life Sciences
Renibus Therapeutics Inc
Rui Nuo Medical Technology (Shanghai) Co Ltd
Sentien Biotechnologies Inc
Sidereal Therapeutics Inc
Silver Creek Pharmaceuticals Inc
Slate Bio Inc
STATegics Inc
Sulfateq BV
TES Pharma SRL
TheraSource LLC
Theratome Bio Inc
Unicycive Therapeutics Inc
Unicyte AG
Valo Health LLC
Vasculonics LLC
Vasomune Inc
vasopharm GmbH
Vivoryon Therapeutics NV
Xigen SA
XORTX Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Acute Renal Failure products market?
The key targets in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase, Alkaline Phosphatase, Free Radical, Peroxisome Proliferator Activated Receptor Delta, Renalase, Alpha 1 Adrenergic Receptor, Alpha 2B Adrenergic Receptor, Atrial Natriuretic Peptide Receptor 1, C-X-C Chemokine Receptor Type 4, and others.
-
What are the key mechanisms of action in the Acute Renal Failure pipeline products market?
The key mechanisms of action in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor Agonist, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase Inhibitor, Alkaline Phosphatase Replacement, Free Radical Scavenger, Peroxisome Proliferator Activated Receptor Delta Agonist, Renalase Activator, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2B Adrenergic Receptor Agonist, Atrial Natriuretic Peptide Receptor 1 Agonist, C-X-C Chemokine Receptor Type 4 Agonist, and others.
-
What are the key routes of administration in the Acute Renal Failure pipeline products market?
The key routes of administration in the Acute Renal Failure pipeline products market are intravenous, oral, subcutaneous, intramuscular, intrathecal, intravenous bolus, parenteral, topical, inhalational, intraarticular, and others.
-
What are the key molecule types in the Acute Renal Failure pipeline products market?
The key molecule types in the Acute Renal Failure pipeline products market are small molecule, recombinant protein, cell therapy, recombinant enzyme, synthetic peptide, fusion protein, antisense RNAi oligonucleotide, biologic, recombinant peptide, monoclonal antibody, and others.
-
Which are the major companies in the Acute Renal Failure pipeline products market?
Some of the major companies in the Acute Renal Failure pipeline products market are Angion Biomedica Corp, Arch Biopartners Inc, Goldilocks Therapeutics Inc, Johnson & Johnson, Mitobridge Inc, Q BioMed Inc, TES Pharma SRL, Alloksys Life Sciences BV, Am-Pharma BV, and Amniotics AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.